LAB/B: Q3 delivered robust sales, margin, and cash flow growth, with strong outlook and disciplined capital use

About this update from Genomma Lab Internacional Sab De Cv Class B

Q3 2024 saw double-digit sales and profit growth, margin expansion, and record cash flow, driven by strong performance in Mexico, the US, and Argentina. Productivity initiatives, brand acquisitions, and disciplined capital allocation support continued growth and margin improvement. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Genomma Lab Internacional Sab De Cv Class B